|
inverse agonism
|
BAO_0002913 |
|
|
full activation
|
BAO_0002914 |
|
|
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
|
CHEBI_50696 |
|
|
peroneal nerve paralysis
|
DOID_6925 |
|
|
lipopolysaccharide biosynthesis inhibitor
|
CHEBI_134108 |
|
|
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
|
CHEBI_50683 |
|
|
antifolate
|
CHEBI_73913 |
|
|
EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor
|
CHEBI_76863 |
|
|
cross-linking reagent
|
CHEBI_50684 |
|
|
reagent
|
CHEBI_33893 |
|
|
lysophosphatidic acid receptor antagonist
|
CHEBI_91193 |
|
|
antiseborrheic
|
CHEBI_59010 |
|
|
neurotic excoriation
|
DOID_9165 |
|
|
protophilic solvent
|
CHEBI_48359 |
|
|
Bronsted base
|
CHEBI_39142 |
|
|
polar solvent
|
CHEBI_48354 |
|
|
polar aprotic solvent
|
CHEBI_48358 |
|
|
aprotic solvent
|
CHEBI_48357 |
|
|
solvent
|
CHEBI_46787 |
|
|
Wiskott-Aldrich syndrome
|
DOID_9169 |
|
